Novel Agents Combining Platelet Activating Factor (PAF) Receptor Antagonist with Thromboxane Synthase Inhibitor (TxSI)
- 13 January 2002
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 12 (5) , 771-774
- https://doi.org/10.1016/s0960-894x(02)00005-7
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- 1,4-Dihydropyridines as antagonists of platelet activating factor. 1. Synthesis and structure-activity relationships of 2-(4-heterocyclyl)phenyl derivativesJournal of Medicinal Chemistry, 1992
- Structure-Activity Studies on Triazolothienodiazepine Derivatives as Platelet-Activating Factor Antagonists.CHEMICAL & PHARMACEUTICAL BULLETIN, 1991
- Is there a case for PAF antagonists in the treatment of ischemie states?Trends in Pharmacological Sciences, 1989
- Clinical Implications of Prostaglandin and Thromboxane A2FormationNew England Journal of Medicine, 1988
- Platelet-activating factor and asthmaJournal of Allergy and Clinical Immunology, 1988
- The role of platelet-activating factor in asthmaJournal of Allergy and Clinical Immunology, 1988
- Platelet Activation in Unstable Coronary DiseaseNew England Journal of Medicine, 1986
- Thromboxane synthetase inhibitors (TXSI). Design, synthesis, and evaluation of a novel series of .omega.-pyridylalkenoic acidsJournal of Medicinal Chemistry, 1985
- CV-3988 - A specific antagonist of platelet activating factor (PAF)Life Sciences, 1983
- Release of Prostaglandins and Thromboxane into the Coronary Circulation in Patients with Ischemic Heart DiseaseNew England Journal of Medicine, 1981